Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.

Wang, Yunwei

Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. [electronic resource] - Journal of gastroenterology and hepatology Dec 2019 - 2090-2095 p. digital

Publication Type: Journal Article

1440-1746

10.1111/jgh.14751 doi


Adolescent
Adult
Aged
Antibodies, Monoclonal, Humanized--adverse effects
Colitis, Ulcerative--drug therapy
Colonoscopy
Crohn Disease--drug therapy
Drug Substitution--methods
Female
Gastrointestinal Agents--adverse effects
Humans
Inflammatory Bowel Diseases--drug therapy
Kaplan-Meier Estimate
Male
Middle Aged
Remission Induction
Retrospective Studies
Severity of Illness Index
Treatment Outcome
Tumor Necrosis Factor Inhibitors--therapeutic use
Young Adult